MENUMENU
  • Covid Clear
  • About Us
        • About Us

          An industry leading services provider in viral challenge studies and laboratory services supporting product development for customers developing antivirals, vaccines and respiratory therapeutics.

          • More about hVIVO
        • Overview
        • Executive Leadership Team
        • Scientific Papers / Abstracts
        • Quality Commitment
        • Ethics & Compliance
        • FluCamp
        • Human Challenge Programme
        • Challenge Agent Manufacturing
        • PrEP Biopharm Ltd
        • Imutex Ltd.
  • Services
        • Human challenge full-service solution
        • human challenge full service solution

          Industry leading provider of viral challenge studies

          • See Our Solution
        • hVIVO Challenge Models
          • Influenza
          • RSV
          • HRV
          • Asthma
          • COPD
          • Cough
        • Laboratory Services
          • Virology
          • Immunology
          • Biomarkers
  • News, Media & Events
        • News, Media & Events

          A source for the latest press releases, scientific publications and other media as well as details of investor and scientific events that we attend and host across the world.

        • News & Media
        • Media Coverage
        • Company News
        • Media Press Kit
        • Videos
        • Events
        • img

          LATEST PRESS RELEASE

          17.02.21 Ethics approval – COVID-19 Human Challenge Study
        • UPCOMING EVENTS

          Proactive Investors One2One Investor Forum

          Thursday 11th March

  • Volunteers
  • Careers
  • Contact Us

Tags

  • asthma & COPD
  • hrv
  • influenza
  • rsv

Scientific Papers / Abstracts: influenza

Scientific Paper 92 : A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity.

Scientific paper 115 – New hVIVO co-authored paper published in Oxford Journals “Open Forum Infectious Diseases” : “A genomic signature of influenza infection shows potential for presymptomatic detection, guiding early therapy, and monitoring clinical responses”

Scientific paper 114 – New hVIVO authored paper published in PLOS One: “Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Challenge Model”

« Previous 1 … 6 7 8

Whether you’re a potential customer, job seeker, health professional or an investor, you can find the best way to contact us from the list below.

Contact Us
  • Terms & Conditions
  • Careers
  • Sitemap
© 2021 Copyright hVIVO Services Limited. All rights reserved. hVIVO Services Limited (“hVIVO”) is registered in England and Wales with registration number 02326557 and registered office at Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2AX, UK.
Privacy Policy | Cookie Policy